Meeting
2014 ASCO Annual Meeting
Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.
Authors
Stephen Maxted Ansell
Mayo Clinic, Rochester, MN
Stephen Maxted Ansell , Anas Younes , Joseph M. Connors , Andrea Gallamini , Won Seog Kim , Jonathan W. Friedberg , Tatyana A. Feldman , Graham Collins , Nancy Bartlett , Jingyuan Wang , Kelly Brady , Jessica Sachs , Dirk Huebner , Naomi N. H. Hunder , John Radford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01712490
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8613)
DOI
10.1200/jco.2014.32.15_suppl.tps8613
Abstract #
TPS8613
Poster Bd #
299A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
First Author: Anas Younes
Poster
2021 ASCO Annual Meeting
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.
First Author: Howland E. Crosswell
Poster
2019 ASCO Annual Meeting
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
First Author: Christine Mauz-Körholz
Poster
2018 ASCO Annual Meeting
KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.
First Author: Christine Mauz-Korholz